Related Experiment Video
Updated: Jul 6, 2026
06:39
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
Secondary myelofibrosis in children
Rahul Naithani1, Seema Tyagi, Ved Prakash Choudhry
1Department of Hematology, All India Institute of Medical Sciences, New Delhi, India. dr_rahul6@hotmail.com
Journal of Pediatric Hematology/Oncology
|April 1, 2008
Summary
Childhood myelofibrosis is rare. Early diagnosis and identifying underlying conditions are crucial for managing this myeloproliferative disorder, as prognosis varies significantly.
Area of Science:
- Pediatric Hematology
- Oncology
- Stem Cell Biology
Background:
- Myelofibrosis is a rare myeloproliferative disorder affecting children.
- It can occur secondary to hematologic malignancies or as an idiopathic condition.
- Understanding its clinical course in children is essential.
Purpose of the Study:
- To describe the clinical course of pediatric myelofibrosis.
- To evaluate the significance of diagnosing underlying conditions.
- To assess the prognostic value of trephine biopsy.
Main Methods:
- Retrospective case series of 6 children diagnosed with myelofibrosis over 6 years.
- Clinical data including diagnosis, treatment, and outcomes were analyzed.
- Trephine biopsy results were reviewed.
Main Results:
- One child responded to steroid therapy.
- One child improved with treatment of an underlying condition.
- Three children died due to their underlying conditions.
- One child was lost to follow-up.
- Trephine biopsy provided diagnostic information but lacked prognostic significance.
Conclusions:
- A comprehensive search for underlying diseases is critical upon diagnosing childhood myelofibrosis.
- Treatment strategies should focus on the underlying etiology.
- Trephine biopsy is useful for diagnosis but not prognosis in pediatric myelofibrosis.
